CITCO |
|
Vaxjo ID |
233 |
|
Vaccine Adjuvant Name |
CITCO |
|
Adjuvant VO ID |
VO_0005720
|
|
Description |
A selective human CAR (constitutive androstane receptor) agonist that induces CYP2B6/CYP2B10 expression to enhance prodrug activation |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
hepatic CYP2B6 by CITCO, a selective human CAR (hCAR) agonist, results in CHOP's enhanced antineoplastic effects in vitro. |
|
Structure |
A synthetic small molecule with imidazo-thiazole and dichlorobenzyl functional groups |
|
Storage |
Stored at −80°C in experimental settings |
|
Preparation |
Dissolved in corn oil for oral (PO) or intraperitoneal (IP) administration at 20 mg/kg |
|
Dosage |
20 mg/kg in mice via IP or oral gavage (PO) |
|
Function |
Results demonstrate that the addition of CITCO to the CHOP regimen leads to significant suppression of the growth of EL-4 xenografts in hCAR-transgenic mice accompanied by reduced expression of cyclin-D1, ki67, Pcna, and increased caspase 3 fragmentation in tumor tissues. |
|
Safety |
Well tolerated in mice; no negative impact on body weight; low systemic exposure; preferential liver accumulation |
| References |
Kurian et al., 2020: Kurian R, Hedrich W, Mackowiak B, Li L, Wang H. CITCO as an Adjuvant Facilitates CHOP-Based Lymphoma Treatment in hCAR-Transgenic Mice. Cells. 2020; 9(11); . [PubMed: 33233444].
|
